CCO Treatment Updates
Advances in the Management of Bone Health and Skeletal Complications in Cancer
Interactive Virtual Presentations
Advances in the Management of Bone Health in Multiple Myeloma
|
|
|
James Berenson, MD, presents cases to illustrate key concepts of bone health in cancer patients, particularly those with multiple myeloma.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Explain the significance of bone disease in cancer in general and in multiple myeloma in particular
- Discuss the risks and benefits of intravenous bisphosphonates for the treatment of bone lesions in multiple myeloma
- Describe the rationale for targeting RANK/RANKL to treat bone loss in cancer
|
Slideset: Advances in the Management of Bone Health in Multiple Myeloma
 |
|
Review the incidence, pathophysiology, and current management of bone complications in multiple myeloma patients. In addition emerging targeted therapies and their modes of action are discussed.
Format: Microsoft PowerPoint (.ppt) |
File size: 2.29 MB
| Date posted: 6/12/2009
|
Advances in the Management of Bone Health in Prostate Cancer
- Matthew R. Smith, MD, PhD
|
|
|
Matthew R. Smith, MD, PhD, reviews the current standard of care and emerging treatment options for prostate cancer patients at risk for bone disease.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Evaluate appropriate therapeutic intervention strategies for managing the effects of cancer and cancer treatment on bone health in prostate cancer patients
- Cite recent clinical trial data on bisphosphonate use to mitigate bone disease of malignancy in prostate cancer patients
- Discuss clinical trial data providing preliminary evidence for RANK ligand as an effective target for inhibiting osteoclast activity and bone destruction
- Illustrate the effects of androgen deprivation therapy on bone health in the setting of prostate cancer
|
Slideset: Advances in the Management of Bone Health in Prostate Cancer
 |
|
Review the current standard of care and examine emerging treatment options for prostate cancer patients at risk of bone disease.
Format: Microsoft PowerPoint (.ppt) |
File size: 2.50 MB
| Date posted: 7/17/2009
|
Bone Health and Skeletal Complications in Breast Cancer
- Robert E. Coleman, MD, FRCP
|
|
|
Robert E. Coleman, MD, FRCP, reviews the current standards of care and emerging treatment options for breast cancer patients at risk for bone disease.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Explain the epidemiology, clinical features, and pathophysiology of bone complications in breast cancer patients
- Cite recent clinical trial data on bisphosphonate use to mitigate bone loss and reduce the incidence of skeletal-related events in breast cancer patients
- Discuss clinical trial data providing preliminary evidence for RANK ligand as an effective target for inhibiting osteoclast activity and bone destruction
|
Slideset: Bone Health and Skeletal Complications in Breast Cancer
 |
|
Review the current standard of care and examine emerging treatment options for breast cancer patients at risk of skeletal complications and bone metastasis.
Format: Microsoft PowerPoint (.ppt) |
File size: 3.83 MB
| Date posted: 8/21/2009
|
Disclaimer:
The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
This program is supported by an educational donation from
Educational grants support only the CME/CE-certified components of this program.
|
|